Guess or get it right?
|
|
- Kelly King
- 6 years ago
- Views:
Transcription
1 Guess or get it right? Antimicrobial prescribing in the 21 st century Robert Masterton
2 Traditional Treatment Paradigm Conservative start with workhorse antibiotics Reserve more potent drugs for non-responders 2
3 New Treatment Paradigm Hit hard and early with appropriate antibiotic(s) Short treatment duration De-escalate escalate where possible 3
4 The Effect of the Traditional Approach Inappropriate therapy (%) Community-acquired infection Hospital-acquired infection Hospital-acquired after prior therapy for community-acquired Kollef et al. Chest 1999;115:
5 Mortality Impact of Inadequate Therapy Garnacho-Montero 5 Luna Álvarez-Lerma Adequate Inadequate Rello Kollef Clec'h Ventilator Associated Pneumonia survivor Luna C, et al. Chest 1997; 111: Álvarez-Lerma F, et al. Intensive Care Med 1996; 22: Rello J, et al AmJ Resp Crit Care Med 1997; 156; Kollef MH, et al. Ann Inter Med 1995; 122: Clec h C, et al. Intensive Xare Med 2004; 30: Garnacho-Montero J, et al. Intensive Care Med 2005; 31:
6 Mortality Impact of Inadequate Therapy 6 Kang** Zaragoza Valles* Ibrahim Adequate Inadequate Bacteremia survivor * Community-acquired bacteremia ** Resistant Gram-Negative microorganisms Ibrahin EH, et al. Chest 2000; 118: Valles J, et al Chest 2003; 123: Zaragoza R, et al. Clin Microbiol Infect 2003; 9; Kang CI, et al. Antimicrob Agents Chemother 2005; 49:
7 What is the new treatment paradigm? Start with the appropriate empiric antibiotic first in nosocomial infections If appropriate, change antibiotic dosage or therapy based on resistance and pathogen information Recognise that prior antimicrobial administration is a risk factor for the presence of resistant pathogens Know the unit s s resistance profile and choose antibiotics accordingly Administer antibiotics at the right dose for the appropriate duration 7
8 Where are we now? What do we know about de-escalation? escalation? What do we know about individual organism/condition settings? What do we know about the best way to use the new treatment paradigm? 8
9 What De-escalation escalation means. Start with broad spectrum appropriate agent Stop if infection unlikely Change to a narrower spectrum agent Use single rather than multiple agents Shorten the course of therapy as much as possible 9 Vidaur. Resp Care 2005, 50:
10 De-escalation escalation in VAP Change of therapy was documented in 56.2% De-escalation escalation = 31.4% (increasing to 38% if isolates were sensitive) De-escalation mortality rate lower than those who continued initial regimen (18% vs 43%; p<0.05) Inappropriate antibiotic therapy = 9% of cases and associated with 14.4% excess mortality De-escalation escalation lower (p <.05) with nonfermenting Gram-negative bacilli (2.7% vs. 49.3%) and in late- onset pneumonia (12.5% vs. 40.7%) When the pathogen remained unknown, half of the patients died and de-escalation escalation was not performed 10 Rello J, et al. Crit Care Med 2004;32:
11 De-escalation escalation in Practice Mortality % De-escalated (n=88) No change (n=245) Escalated (n=61) 11 % Patterns of Modification Quinolone Ureido/Mono Cefepime Carbapenem Kollef MH. Chest 2006; 129:
12 Guidelines and De-escalation escalation 12 ICU imipenem-based regimen After D3, therapy based on susceptibility results Better empirical cover (81 vs 46%; p<0.01) No change in imipenem resistance rates Soo Hoo et al. Chest 2005;128:
13 How to improve de-escalation? escalation? Tracheal Aspirate (n = 81) De-escal escal (21%) No BAL (n=62) De-escal escal (66%) No 13 15D Mortality 28D Mortality LOS ICU LOS Hospital * = p < % 34.3% 4.8% 23.8% 11.6% 45.3% 12.1% 38% / / / / /- 4.4* / /- 2.4* / Giantsou et al. Intensive Care Med. 2007:33:
14 De-escalation escalation Dilemmas 14 When to de-escalate escalate to a stop Day 3 and Microbiology negative No Systemic Inflammatory Response Syndrome (SIRS) White blood cell count and temperature not markedly and increasingly abnormal When not to de-escalate escalate and to consider escalation Day 3 and Microbiology negative Patient clinically septic SIRS Markedly abnormal temperature Markedly abnormal white blood cell count
15 Do you practice de-escalation therapy? 1. Yes 2. No 82% 18% 15 Yes No
16 In my unit, most of my colleagues practice de-escalation: escalation: 1. True 2. False 58% 42% 16 True False
17 New data disease specific ESBL Predictors of mortality in patients with BSI caused by ESBL-producing Enterobacteriaceae p<0.001 Mortality (%) Inadequate initial therapy (n=89) Adequate initial therapy (n=97) 17 n=186 Tumbarello et al. Antimicrob Agents Chemother 2007;51:
18 New data disease specific ESBL Clinical impact of bacteraemia with ESBL-producing Enterobacteriaceae Cases Controls Incidence (%) Mortality Mortality due to infection Delay in appropriate therapy Discharged to chronic care 18 All differences = p < 0.05 Schwaber et al. Antimicrob Agents Chemother 2006; 50:
19 New data recognising the risks! Risk factors for inadequate treatment of VAP = Multidrug-resistant resistant bacteria (OR = 3.07), polymicrobial infection (OR = 3.67) and late-onset VAP (OR = 2.93) Adequate treatment n=82 Inadequate treatment n= Cumulative survival Adequate Inadequate Time after VAP onset (days) Teixeira et al. J Hosp Infect 2007;65:
20 New data the speed of delay! Survivial (%) Each hour of delay carries 7.6% reduction in survival Delay in treatment (hours) from hypotension onset Kumar et al. Crit Care Med 2006; 34:
21 New data the time window 142 patients, 3 intensive care units (ICUs) in France, invasive diagnosis for ventilator- associated pneumonia (VAP) Adequate vs inadequate antibiotic therapy on Day 0 Adequate antibiotic therapy on Day 2 rises to 92% LOD score 4 4 (n=70) Median (range) LOD at first suspicion of VAP Median (range) SAPS II at first suspicion of VAP Adequate antibiotic (n=63) Inadequate antibiotic (n=79) P-value 3 (2 4) 3 (2 4) (28 37) 35 (29 40) 0.79 ICU death 2/27 (7%) 16/43 (37%) Hospital death 4/27 (15%) 19/43 (44%) 0.01 LOD = logistic organ dysfuncftion SAPS II = simplied acute physiologic score 21 Clec`h et al. Intensive Care Med 2004;30:
22 New data do not wait for results! Mortality (%) n= Switching after susceptibility results p< Adequate treatment within a a few hours 22 Tumbarello et al. Antimicrob Agents Chemother 2007;51:
23 New data putting things together Effect of 2 day delay in appropriate therapy for 30-day mortality in Pseudomonas spp. bacteraemia 50 44% p= day mortality (%) % 20% 19% 23 0 < >52 Delay in appropriate therapy (hours) Lodise et al. Antimicrob Agents Chemother 2007;51:
24 New data is right a constant? Non-survivors Survivors p< p=0.24 p= n=97 40 p= Patients (%) Aminoglycosides (n=20) β-lactam/ β-lactamase inhibitors (n=33) Carbapenems (n=28) Ciprofloxacin (n=16) 24 4 of Cipro failed isolates had a mutation at codon 83 of gyra, and other 4 qnrb gene detected Tumbarello et al. Antimicrob Agents Chemother 2007;51:
25 New data right and resistance Non-adequate Adequate 30 Frequency (%) Number of resistances Frequency of the appropriateness of empiric antimicrobial therapy (a) and proportion of deaths (b) in relation to the number of antibiotics to which the E. coli isolated from blood cultures was non-susceptible Peralta et al. J Antimicrob Chemother 2007;60:
26 New data right and resistance 20 Dead Mortality (%) Surviving Adequacy of empiric antibiotic treatment is an independent risk factor for mortality in E. coli bacteraemia Number of resistances Peralta et al. J Antimicrob Chemother 2007;60:
27 New data cost and the paradigm ESBL production in Enterobacteriaceae bacteremia Outcome Mortality Length of stay Delay in appropriate therapy Cost of hospitalisation OR (95% CI) or ME 3.6 ( ) ( ) 1.57 P-value < CI, confidence interval; ME, multiplicative effect 27 Schwaber et al. Antimicrob Agents Chemother 2006; 50:
28 New data cost and the paradigm Economic impact of bacteraemia with ESBL-producing Enterobacteriaceae Cost (US$) Cases Controls Cost of short-term term meropenem treatment: 1 week: days: Mean increase in equivalent cost attributable to ESBL production is $9620 ( 5288) 0 28 Average hospital cost Schwaber et al. Antimicrob Agents Chemother 2006; 50:
29 ESBL rapid testing to improve outcomes Outcome E-test (167) Control (83) P Test Fever; mean days ± SD 4.61 ± ± 6.24 < 0.01 Antibiotic therapy; mean days ± SD ± ± DDD: mean days ± SD ± ± Median cost ( ) 666 ( ) 984 ( % adequate days of antibiotic < 0.01 % adequate days DDD antibiotic < 0.01 CDAD; number & percentage 3 (1.8) 8 (9.6) < 0.01 Median days ventilated post VAP 8 (3-19) 12 (6-21) episodes of VAP Bouza et al. Clin Infect Dis. 2007;44:
30 How best to get the best? The Care Bundle Approach Specifically selected care elements From evidence based guidelines Implemented together provide improved outcomes compared to individual elements alone 30
31 The New Paradigm in a Care Bundle Secondary analysis of prospective before after study Intervention: ED sepsis bundle Bundle components Patient identification Fluid resuscitation Vasopressor administration Antibiotic recommendations 31 Shorr et al. Crit Care Med. 2007;35:
32 The New Paradigm in a Care Bundle Mortality reduced with protocol from 48.3% to 30.0% (p=0.04) Total Group Survivors Cost per patient (US $) p=0.009 Total cost (US $) Before Group After Before Group After Shorr et al. Crit Care Med. 2007;35:
33 The New Paradigm in a Care Bundle 2,000 Before After 1,600 Costs (US$ x 1000) 1, Total cost differential: $573, Total ICU Ward Pharmacy Lab Rad RT ED OR Misc Shorr et al. Crit Care Med. 2007;35:
34 The New Paradigm in a Care Bundle Reduction in LOS is main driver of costs Pre-intervention Post-intervention Proportion of subjects remaining hospitalised p= Median LOS Pre: 10 days Post: 7.5 days Length of stay (days) Shorr et al. Crit Care Med. 2007;35:
35 Conclusions 35 What we know: Getting it right first time in serious sepsis is proven Treatment must be guided by local data The new paradigm is just a part of sepsis management The new paradigm saves lives and money What we do not know Where does the new paradigm not work How can the new paradigm best be implemented What is the full picture of benefits realisation against the new paradigm
HAP/VAP care bundle interventions - a UK approach. Dr R G Masterton NHS Ayrshire & Arran
HAP/VAP care bundle interventions - a UK approach Dr R G Masterton NHS Ayrshire & Arran How Hazardous Is Health Care? (Leape and Amalberti) Total lives lost per year 100,000 10,000 1,000 100 10 1 HAZARDOUS
More informationContinuous Infusion of Antibiotics In The ICU: What Is Proven? Professor of Medicine Vice-Chairman, Department of Medicine SUNY at Stony Brook
Continuous Infusion of Antibiotics In The ICU: What Is Proven? Michael S. Niederman, M.D. Chairman, Department of Medicine Winthrop-University Hospital Mineola, NY Professor of Medicine Vice-Chairman,
More informationGuidelines. 14 Nov Marc Bonten
Guidelines 14 Nov 2014 Marc Bonten Treatment of Community-Acquired Pneumonia SWAB/ NVALT guideline 2011, replaced SWAB guideline 2005 Empirical treatment must cover the most likely causative pathogen.
More informationMDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES
MDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES 1 Marin H. Kollef, MD Professor of Medicine Virginia E. and Sam J. Golman Chair in Respiratory Intensive Care Medicine Washington University School of
More informationOutline. Pharmacists Improving Outcomes in the Management of. of Infectious Diseases. Threats Against Desired Outcomes 7/11/2010
Pharmacists Improving Outcomes in the Management of Infectious Diseases Christine Teng, MSc(Clin Pharm) BCPS Assistant Professor Dept of Pharmacy, National University of Singapore Principal Pharmacist
More informationHEALTHCARE-ASSOCIATED PNEUMONIA: DIAGNOSIS, TREATMENT & PREVENTION
HEALTHCARE-ASSOCIATED PNEUMONIA: DIAGNOSIS, TREATMENT & PREVENTION David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics, & Epidemiology Associate Chief Medical Officer, UNC Health Care Medical
More informationAminoglycosides as an antibiotic class maintain
SURGICAL INFECTIONS Volume 17, Number 3, 2016 ª Mary Ann Liebert, Inc. DOI: 10.1089/sur.2015.276 An Argument for the Use of Aminoglycosides in the Empiric Treatment of Ventilator-Associated Pneumonia Addison
More informationAbstract. Introduction
ORIGINAL ARTICLE INFECTIOUS DISEASES Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care
More informationPharmacologyonline 1: (2010) ewsletter Singh and Kochbar. Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of
Optimizing Pharmacokinetic/Pharmacodynamics Principles & Role of Cefoperazone Sulbactam Singh M*, Kochhar P* Medical & Research Division, Pfizer India. Summary Antimicrobial resistance is associated with
More informationA Snapshot of Colistin Use in South-East Europe and Particularly in Greece
A Snapshot of Colistin Use in South-East Europe and Particularly in Greece Helen Giamarellou 02.05.2013 When Greek Physicians Prescribe Colistin? It is mainly prescribed in the ICU for VAP, bacteremia
More informationInadequate Empiric Antibiotic Therapy among Canadian. Hospitalized Solid-Organ Transplant Patients: Incidence and Impact on Hospital Mortality
Inadequate Empiric Antibiotic Therapy among Canadian Hospitalized Solid-Organ Transplant Patients: Incidence and Impact on Hospital Mortality by Bassem Hamandi A thesis submitted in conformity with the
More informationESCMID Online Lecture Library. by author
Microbiological evaluation: how to report the results Alvaro Pascual MD, PhD Infectious Diseases and Clinical Microbiology Unit. University Hospital Virgen Macarena University of Sevilla BSI management
More informationFrom the labo to the ICU: Surveillance cultures in daily ICU practice. Pieter Depuydt MD PhD Dept. Intensive Care Ghent University Hospital
From the labo to the ICU: Surveillance cultures in daily ICU practice Pieter Depuydt MD PhD Dept. Intensive Care Ghent University Hospital Question 1: What is the current practice of surveillance cultures
More informationSepsis Treatment: Early Identification Remains the Key Issue
Sepsis Treatment: Early Identification Remains the Key Issue Marin H. Kollef, MD Professor of Medicine Washington University School of Medicine Director, Medical Critical Care Director, Respiratory Care
More informationPotential Conflicts of Interests
Potential Conflicts of Interests Research Grants Agency for Healthcare Research and Quality Akers Bioscience, Inc. Pfizer, Inc. Scientific Advisory Boards Pfizer, Inc. Cadence Pharmaceuticals Kimberly
More informationOvercoming the PosESBLities of Enterobacteriaceae Resistance
Overcoming the PosESBLities of Enterobacteriaceae Resistance Review of current treatment options Jamie Reed, PharmD Pharmacy Grand Rounds August 28, 2018 Rochester, MN 2018 MFMER slide-1 Disclosure No
More informationICU Volume 11 - Issue 3 - Autumn Series
ICU Volume 11 - Issue 3 - Autumn 2011 - Series Impact of Pharmacokinetics of Antibiotics in ICU Clinical Practice Introduction The efficacy of a drug is mainly dependent on its ability to achieve an effective
More informationThe Clinical Management of Hospital Acquired Pneumonia. NHS Ayrshire & Arran
The Clinical Management of Hospital Acquired Pneumonia Dr R G Masterton NHS Ayrshire & Arran What s new in HAP/VAP? Care bundles MRSA VAP Improving outcomes with current antimicrobial New antimicrobials
More informationMarcos I. Restrepo, MD, MSc, FCCP
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationCommunity Acquired & Nosocomial Pneumonias
Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP
More informationOriginal Article Mahidol Univ J Pharm Sci 2015; 42 (4), MT. Nguyen 1, TD. Dang Nguyen 1* 1
Original Article Mahidol Univ J Pharm Sci 2015; 42 (4), 195-202 Investigation on hospital-acquired pneumonia and the association between hospital-acquired pneumonia and chronic comorbidity at the Department
More informationBrice Taylor Assistant Professor Division of Pulmonary and Critical Care Medicine
Brice Taylor Assistant Professor Division of Pulmonary and Critical Care Medicine Discuss advances in predicting prognosis Understand dwhat we know (and don t know) about the Microbiology Recognize important
More informationDilemmas in Septic Shock
Dilemmas in Septic Shock William Janssen, M.D. Assistant Professor of Medicine National Jewish Health University of Colorado Denver Health Sciences Center A 62 year-old female presents to the ED with fever,
More informationExpert rules. for Gram-negatives
Academic Perspective in Expert rules Emerging Issues of Resistance in Gram-ve Bacteria for Gram-negatives Trevor Winstanley Sheffield Teaching Hospitals Presented on behalf of David Livermore University
More informationChoc septique. Frédéric Pène
Choc septique Frédéric Pène Réanimation Médicale, Hôpital Cochin, AP-HP Université Paris Descartes Institut Cochin, Inserm U1016, CNRS UMR-8104, Département 3i No conflict of interest A 54 y.o. male patient
More informationβ- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication
Prevalence of Carbapenem-Hydrolyzing β- Lactamase Gene carrying Klebsiella pneumoniae and its Clinical Implication David Alcid M.D Balaji Yegneswaran M.D. Wanpen Numsuwan Introduction Klebsiella pneumoniae
More informationDiagnosis of Ventilator- Associated Pneumonia: Where are we now?
Diagnosis of Ventilator- Associated Pneumonia: Where are we now? Gary French Guy s & St. Thomas Hospital & King s College, London BSAC Guideline 2008 Masterton R, Galloway A, French G, Street M, Armstrong
More informationPortugal. From SACiUCI to InfAUCI. Sepsis epidemiology: an update. You re only given a little spark of madness. You mustn t lose it.
Sepsis epidemiology: an update Portugal João Gonçalves Pereira ICU director Vila Franca Xira Hospital From SACiUCI to InfAUCI You re only given a little spark of madness. You mustn t lose it. Robin Williams
More informationALERT. Clinical microbiology considerations related to the emergence of. New Delhi metallo beta lactamases (NDM 1) and Klebsiella
ALERT Clinical microbiology considerations related to the emergence of New Delhi metallo beta lactamases (NDM 1) and Klebsiella pneumoniae carbapenemases (KPC) amongst hospitalized patients in South Africa
More informationClinical characteristics of health care-associated pneumonia in a Korean teaching hospital
Respiratory Medicine (2010) 104, 1729e1735 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Clinical characteristics of health care-associated pneumonia in a Korean teaching
More informationLessons from recent studies. João Gonçalves Pereira UCIP DALI
Lessons from recent studies João Gonçalves Pereira UCIP DALI 1 Patterns of Antimicrobial Activity Concentration C max Aminoglycosides Cmax/MIC>10 Metronidazol Area under the concentration curve Azithromycin
More informationLa neutropenia febbrile
XII Corso Avanzato di Terapia Antibiotica Pisa, 15-16 novembre 2017 La neutropenia febbrile Alessandra Micozzi Dipartimento di Biotecnologie Cellulari ed Ematologia Sapienza Università di Roma Fever developing
More informationSepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment
Sepsis new definitions of sepsis and septic shock and Novelities in sepsis treatment What is sepsis? Life-threatening organ dysfunction caused by a dysregulated host response to infection A 1991 consensus
More informationPHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS
PHARMACOKINETIC & PHARMACODYNAMIC OF ANTIBIOTICS SITI HIR HURAIZAH MD TAHIR Bpharm (UKM), MSc (Clinical Microbiology) (UoN) CLINICAL PHARMACIST HOSPITAL MELAKA WHY STUDY PHARMACOKINETICS (PK) AND PHARMACODYNAMICS
More informationOptimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches
Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator
More informationEducational Workshop
Educational Workshop EW02: Management of severe sepsis and septic shock anno 2015 Arranged with ESGBIS & International Sepsis Forum (ISF) Convenors: W. Joost Wiersinga, Amsterdam, NL Tom van der Poll,
More informationInfections In Cirrhotic patients. Dr Abid Suddle Institute of Liver Studies King s College Hospital
Infections In Cirrhotic patients Dr Abid Suddle Institute of Liver Studies King s College Hospital Infection in cirrhotic patients Leading cause morbidity/mortality Common: 30-40% of hospitalised cirrhotic
More informationBC Sepsis Network Emergency Department Sepsis Guidelines
The provincial Sepsis Clinical Expert Group developed the BC, taking into account the most up-to-date literature (references below) and expert opinion. For more information about the guidelines, and to
More informationTerapia delle infezioni da Pseudomonas aeruginosa MDR
Verona 23 ottobre 2010 Terapia delle infezioni da Pseudomonas aeruginosa MDR Pierluigi Viale Clinica di Malattie Infettive Policlinico S. Orsola Malpighi Global resistance surveillance of Pseudomonas aeruginosa
More informationOHSU. Update in Sepsis
Update in Sepsis Jonathan Pak, MD June 1, 2017 Structure of Talk 1. Sepsis-3: The latest definition 2. Clinical Management - Is EGDT dead? - Surviving Sepsis Campaign Guidelines 3. A novel therapy: Vitamin
More informationHospital-acquired Pneumonia
Hospital-acquired Pneumonia Hospital-acquired pneumonia (HAP) Pneumonia that occurs at least 2 days after hospital admission. The second most common and the leading cause of death due to hospital-acquired
More informationGiving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help?
Giving the Proper Dose: How Can The Clinical and Laboratory Standards Institute(CLSI)Help? Pranita D. Tamma, M.D., M.H.S. Director, Pediatric Antimicrobial Stewardship Johns Hopkins University School of
More informationImpact of Extended Spectrum Beta-Lactamase Producing Klebsiella pneumoniae Infections in Severely Burned Patients
Impact of Extended Spectrum Beta-Lactamase Producing Klebsiella pneumoniae Infections in Severely Burned Patients Jason W Bennett, MD, MSPH, Janelle L Robertson, MD, Duane R Hospenthal, MD, PhD, Steven
More informationProspective audit and feedback of piperacillin-tazobactam use in a 1115 bed acute care hospital
Prospective audit and feedback of piperacillin-tazobactam use in a 1115 bed acute care hospital Final Results Nathan Beahm, BSP, PharmD(student) September 10, 2016 Objectives Review background information
More informationP. aeruginosa: Present therapeutic options in Intensive Care. Y. Van Laethem (CHU St-Pierre & Université libre de Bruxelles, Brussels, Belgium)
P. aeruginosa: Present therapeutic options in Intensive Care Y. Van Laethem (CHU St-Pierre & Université libre de Bruxelles, Brussels, Belgium) Activity vs Pseudomonas aeruginosa Pseudomonas aeruginosa
More informationUrinary Tract Infections: From Simple to Complex. Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014
Urinary Tract Infections: From Simple to Complex Adriane N Irwin, MS, PharmD, BCACP Clinical Assistant Professor Ambulatory Care October 25, 2014 Learning Objectives Develop empiric antimicrobial treatment
More informationThe Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia JORDI RELLO, MIGUEL GALLEGO, DOLORS MARISCAL, ROSARIO SOÑORA, and JORDI VALLES Intensive Care, Respiratory and Microbiology
More informationPREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS
PREVENTION AND TREATMENT OF BACTERIAL INFECTIONS IN CIRRHOSIS Dr. J. Fernández. Head of the Liver Unit Hospital Clinic Barcelona, Spain AEEH Postgraduate Course, Madrid, February 15 2017 Prevalence of
More informationLa farmacologia in aiuto
Ferrara, 15 giugno 2018 La farmacologia in aiuto Pier Giorgio Cojutti, Federico Pea Istituto di Farmacologia Clinica Azienda Sanitaria Universitaria Integrata di Udine Therapeutic Drug Monitoring of Beta-Lactams
More informationSepsi: nuove definizioni, approccio diagnostico e terapia
GIORNATA MONDIALE DELLA SEPSI DIAGNOSI E GESTIONE CLINICA DELLA SEPSI Giovedì, 13 settembre 2018 Sepsi: nuove definizioni, approccio diagnostico e terapia Nicola Petrosillo Società Italiana Terapia Antiinfettiva
More informationAntibiotics for ventilator-associated pneumonia(review)
Cochrane Database of Systematic Reviews Antibiotics for ventilator-associated pneumonia(review) ArthurLE,KizorRS,SelimAG,vanDrielML,SeoaneL ArthurLE,KizorRS,SelimAG,vanDrielML,SeoaneL. Antibiotics for
More informationPresented at the annual meeting of the American Society of Microbiology, June 1-5, 2017, New Orleans, LA, USA
Is Associated With Improved Survival and Safety Compared to Colistin in Serious Carbapenemresistant Enterobacteriaceae (CRE) Infections: Results of the CARE Study Lynn E. Connolly 1, Adrian M. Jubb 1,
More informationCare Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: All MHS employed providers within Primary Care, Urgent Care, and In-Hospital Care. The secondary audience
More informationCURRENT GUIDELINES FOR SEPSIS MANAGEMENT
HELLENIC SEPSIS STUDY GROUP www.sepsis.gr CURRENT GUIDELINES FOR SEPSIS MANAGEMENT Evangelos J. Giamarellos-Bourboulis, MD, PhD Associate Professor of Medicine 4 th Department of Internal Medicine, National
More informationSepsis. Reliability- can we achieve Dr Ron Daniels
Sepsis. Reliability- can we achieve it? @SepsisUK Dr Ron Daniels Chief Executive, Global Sepsis Alliance Fellow: NHS Improvement Faculty Chief Executive: United Kingdom Sepsis Trust & Chair, UK SSC RRAILS
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationavailable at journal homepage:
Journal of Microbiology, Immunology and Infection (2011) 44, 282e288 available at www.sciencedirect.com journal homepage: www.e-jmii.com ORIGINAL ARTICLE Clinical manifestations and prognostic factors
More informationVentilator Associated
Ventilator Associated Pneumonia: Key and Controversial Issues Christopher P. Michetti, MD, FACS Inova Fairfax Hospital, Falls Church, VA Forrest Dell Moore, MD, FACS Banner Healthcare System, Phoenix,
More informationEnterobacter aerogenes
Enterobacter aerogenes Piagnerelli M 1, Carlier E 1, Deplano A 3, Lejeune P 1, Govaerts D 2 1 Departments of Intensive Care and 2 Microbiology, A. Vésale Hospital. 6110 Montigny-le-Tilleul. 3 Department
More informationSevere and Tertiary Peritonitis
Severe and Tertiary Peritonitis Addison K. May, MD FACS Professor of Surgery and Anesthesiology Division of Trauma and Surgical Critical Care Vanderbilt University Medical Center PS204: The Bad Infections:
More informationClinical Epidemiology of Gram-Negative Bacilli Bacteremia in a U.S. Teaching Hospital. The Impact of Multi-drug Resistance on Outcome
Clinical Epidemiology of Gram-Negative Bacilli Bacteremia in a U.S. Teaching Hospital The Impact of Multi-drug Resistance on Outcome By Christopher Hostler A Master s Paper submitted to the faculty of
More informationLa batteriocidia sierica: passato e presente
Genova, 23 settembre 2016 La batteriocidia sierica: passato e presente Dott.ssa Maddalena Giannella Clinica di Malattie Infettive AOU Policlinico Sant Orsola Malpighi Case 1 Case 2 Summary: Cured of cancer
More informationHealthcare-associated infections acquired in intensive care units
SURVEILLANCE REPORT Annual Epidemiological Report for 2015 Healthcare-associated infections acquired in intensive care units Key facts In 2015, 11 788 (8.3%) of patients staying in an intensive care unit
More informationHEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY
HEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics, & Epidemiology Associate Chief Medical Officer, UNC Health
More informationTreatment Strategies for Infections due to MDR-GNR
Treatment Strategies for Infections due to MDR-GNR Michael Satlin, MD Instructor in Medicine Division of Infectious Diseases Weill Cornell Medical College, New York, NY October 16, 2012 1 2 Faculty Disclosure
More informationClinical Trial Data Supporting FDA Clearance of the T2Bacteria Panel Versus Blood Culture for the Diagnosis of Bacteremia
Clinical Trial Data Supporting FDA Clearance of the T2Bacteria Panel Versus Blood Culture for the Diagnosis of Bacteremia New diagnostic test overcomes time, sensitivity, and antimicrobial interference
More informationConsequences for the clinicians
30th Symposium : What will change in your daily practice with the new Elewijt, 26-05-2008 EUCAST breakpoints for antibiotic susceptibility testing Consequences for the clinicians Y.Van Laethem,MD CHU St
More informationLinezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Shorr A F, Susla G M, Kollef M H
Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Shorr A F, Susla G M, Kollef M H Record Status This is a critical abstract of an economic evaluation
More informationEmpirical Antibiotic Therapy Combo vs Mono : Best
Empirical Antibiotic Therapy Combo vs Mono : Best Anand Kumar MD, FRCPC, FCCP, FCCM Professor of Medicine University of Manitoba Health Sciences Centre St. Boniface Hospital Winnipeg, Manitoba For available
More informationUse of imipenem. with the support of Wallonie-Bruxelles International. Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles
with the support of Wallonie-Bruxelles International Use of imipenem Magali Dodémont Microbiology Hospital Erasme Université Libre de Bruxelles 1 Β-lactams classification 2 Β-lactams: mode of action Inhibition
More informationCARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: The target audience for this Care Guideline is all MultiCare providers and staff, including those associated with our clinically integrated
More informationPredictive scoring model of mortality in Gram-negative bloodstream infection
ORIGINAL ARTICLE INFECTIOUS DISEASES Predictive scoring model of mortality in Gram-negative bloodstream infection M. N. Al-Hasan 1,2, B. D. Lahr 3, J. E. Eckel-Passow 3 and L. M. Baddour 2 1) Department
More informationCurrent concepts in combination antibiotic therapy for critically ill patients
Short Communication Current concepts in combination antibiotic therapy for critically ill patients Armin Ahmed, Afzal Azim, Mohan Gurjar, Arvind Kumar Baronia Abstract Widespread emergence of multidrug
More informationBiomarkers in sepsis: Utility in critical care
Biomarkers in sepsis: Utility in critical care Fathima Paruk, PhD Charlotte Maxeke Johannesburg Academic Hospital and University of Witwatersrand Kumar A et al, Chest 2009; 136:1237-48. von Gunten et al
More informationVentilator-associated pneumonia after pediatric cardiac surgery in southern Taiwan
J Microbiol Immunol Infect. 2009;42:413-419 Ventilator-associated pneumonia after pediatric cardiac surgery in southern Taiwan Chia-Wan Tang 1, Po-Yen Liu 1, Yung-Feng Huang 1, Jun-Yen Pan 2, Susan Shin-Jung
More informationImpact of Inactive Empiric Antimicrobial Therapy on Inpatient Mortality and Length of Stay
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Oct. 2006, p. 3355 3360 Vol. 50, No. 10 0066-4804/06/$08.00 0 doi:10.1128/aac.00466-06 Copyright 2006, American Society for Microbiology. All Rights Reserved. Impact
More informationORIGINAL ARTICLE /j x. Greece; and 4 Tufts University School of Medicine, Boston, MA, USA
ORIGINAL ARTICLE 10.1046/j.1469-0691.2004.01043.x Colistin treatment in patients with ICU-acquired infections caused by multiresistant Gram-negative bacteria: the renaissance of an old antibiotic A. S.
More informationMICHIGAN MEDICINE GUIDELINES FOR TREATMENT OF URINARY TRACT INFECTIONS IN ADULTS
When to Order a Urine Culture: Asymptomatic bacteriuria is often treated unnecessarily, and accounts for a substantial burden of unnecessary antimicrobial use. National guidelines recommend against testing
More informationCefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
Fukuchi et al. BMC Infectious Diseases (2016) 16:427 DOI 10.1186/s12879-016-1770-1 RESEARCH ARTICLE Open Access Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems
More informationA Two-Year Analysis of Risk Factors and Outcome in Patients with Bloodstream Infection
Jpn. J. Infect. Dis., 56, 1-7, 2003 Original Article A Two-Year Analysis of Risk Factors and Outcome in Patients with Bloodstream Infection Andrea Endimiani, Antonio Tamborini, Francesco Luzzaro, Gianluigi
More informationAndrea Blotsky MDCM FRCPC General Internal Medicine, McGill University Thursday, October 15, 2015
The TIMES Project: (Time to Initiation of Antibiotic Therapy in Medical Patients Presenting to the Emergency Department with Sepsis) - Preliminary Findings Andrea Blotsky MDCM FRCPC General Internal Medicine,
More informationBMJ Open. For peer review only -
BMJ Open TREATMENT OF FEBRILE GERIATRIC PATIENTS WITH SUSPECTED URINARY TRACT INFECTIONS IN A HOSPITAL WITH HIGH RATES OF ESBL PRODUCING BACTERIA Journal: BMJ Open Manuscript ID bmjopen-0-0 Article Type:
More informationVentilator-associated pneumonia related to ESBL-producing gram negative bacilli
Review Article Page 1 of 6 Ventilator-associated pneumonia related to ESBL-producing gram negative bacilli Benoit Pilmis 1, Jean-Ralph Zahar 2,3 1 Antimicrobial Stewardship Team, Hospital Paris Saint Joseph,
More informationVentilator Associated Pneumonia. ICU Fellowship Training Radboudumc
Ventilator Associated Pneumonia ICU Fellowship Training Radboudumc Attributable mortality VAP Meta-analysis of individual patient data from randomized prevention studies Attributable mortality mainly results
More informationInstitute of Hygiene and Environmental Medicine. Charité University Medicine Berlin. Mail:
AAC Accepts, published online ahead of print on 13 April 2009 Antimicrob. Agents Chemother. doi:10.1128/aac.01070-08 Copyright 2009, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationPrevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
ISSN: 2319-7706 Volume 3 Number 10 (2014) pp. 474-478 http://www.ijcmas.com Original Research Article Prevalence of Extended Spectrum -Lactamases In E.coli and Klebsiella spp. in a Tertiary Care Hospital
More informationAffinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and ACCEPTED
AAC Accepts, published online ahead of print on February 00 Antimicrob. Agents Chemother. doi:./aac.01-0 Copyright 00, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights
More informationVentilator Associated Pneumonia. ICU Fellowship Training Radboudumc
Ventilator Associated Pneumonia ICU Fellowship Training Radboudumc Attributable mortality VAP Meta-analysis of individual patient data from randomized prevention studies Attributable mortality mainly results
More informationNONFERMENTING GRAM NEGATIVE RODS. April Abbott Deaconess Health System Evansville, IN
NONFERMENTING GRAM NEGATIVE RODS April Abbott Deaconess Health System Evansville, IN OBJECTIVES Discuss basic limitations to assessing carbapenem resistance in nonfermenting GNRs Discuss antimicrobial
More informationTherapeutic drug monitoring of β-lactams
CORATA Belgique Reims 1-2/10/2014 Therapeutic drug monitoring of β-lactams Frédéric Cotton Clinical Chemistry Erasme Hospital Faculty of Pharmacy ULB TDM of β-lactams β-lactams pharmacokinetics pharmacodynamics
More informationOrchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department
Orchestrated Efforts to Optimize Antibiotic Prescriptions in a Medical Department Dr. Eugene Tso Division of Infectious Diseases Department of Medicine & Geriatrics United Christian Hospital 11 May 2010
More informationClinical Practice Management Guideline for Ventilator-Associated Pneumonia: Diagnosis, Treatment & Prevention
Clinical for Ventilator-Associated Pneumonia: Diagnosis, Treatment & Prevention Background Ventilator-associated pneumonia (VAP), a pneumonia that develops 48hrs after initiation of mechanical ventilation,
More informationOutcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections
ORIGINAL ARTICLE BACTERIOLOGY Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infections D. Ben-David, R. Kordevani, N. Keller, I. Tal, A. Marzel, O. Gal-Mor, Y. Maor and G. Rahav Infectious
More informationRAPID COMMUNICATION. Maura S. de Oliveira, I Silvia Figueiredo Costa, II Ewerton de Pedri, II Inneke van der Heijden, II Anna Sara S.
RAPID COMMUNICATION The minimal inhibitory concentration for sulbactam was not associated with the outcome of infections caused by carbapenem-resistant Acinetobacter sp. treated with ampicillin/sulbactam
More informationPseudomonas aeruginosa: Evolution of Antimicrobial Resistance and Implications for Therapy
44 Pseudomonas aeruginosa: Evolution of Antimicrobial Resistance and Implications for Therapy Kate McCarthy, MBBS, FRACP, FRCPA 1 1 University of Queensland, UQ Centre for Clinical Research, Brisbane,
More informationRobert A. Weinstein, MD Stroger (Cook County) Hospital Rush Medical College April 6, Disclosure: Grant funding from CDC & Sage Products, Inc.
Robert A. Weinstein, MD Stroger (Cook County) Hospital Rush Medical College April 6, 2010 Disclosure: Grant funding from CDC & Sage Products, Inc. How the BLEEP should I know? Only problem how we gonna
More informationIntracheal antibiotics administration
Intracheal antibiotics administration Jean Chastre, M.D. www.reamedpitie.com Disclosure Conflicts of interest: Consulting or Lecture fees: Bayer, Pfizer, Cubist/Merck, Basilea, Kenta/Aridis, Roche, AstraZeneca/Medimmune
More informationOutpatient treatment in women with acute pyelonephritis after visiting emergency department
LETTER TO THE EDITOR Korean J Intern Med 2017;32:369-373 Outpatient treatment in women with acute pyelonephritis after visiting emergency department Hee Kyoung Choi 1,*, Jin-Won Chung 2, Won Sup Oh 3,
More informationANWICU knowledge
ANWICU knowledge www.anwicu.org.uk This presenta=on is provided by ANWICU We are a collabora=ve associa=on of ICUs in the North West of England. Permission to provide this presenta=on has been granted
More informationTreatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae
Treatment Options for Urinary Tract Infections Caused by Extended-Spectrum Β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae medicine.missouri.edu/jahm/treatment-options-urinary-tract-infections-caused-extended-spectrum-β-lactamase-producingescherichia-coli-klebsiella-pneumoniae/
More information